Can-Fite BioPharma Ltd.
CANF · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $1 | $1 |
| % Growth | -9.3% | -8.3% | -5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1 | $1 | $1 | $1 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $6 | $6 | $8 | $10 |
| G&A Expenses | $3 | $3 | $3 | $4 |
| SG&A Expenses | $3 | $3 | $3 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $9 | $9 | $11 | $14 |
| Operating Income | -$8 | -$8 | -$10 | -$13 |
| % Margin | -1,206.2% | -1,103% | -1,246.4% | -1,505.5% |
| Other Income/Exp. Net | $0 | $1 | -$0 | $0 |
| Pre-Tax Income | -$8 | -$8 | -$10 | -$13 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$8 | -$8 | -$10 | -$13 |
| % Margin | -1,169.1% | -1,027.5% | -1,255.9% | -1,476.6% |
| EPS | -1.08 | -1.8 | -3.75 | -9 |
| % Growth | 40% | 52% | 58.3% | – |
| EPS Diluted | -1.08 | -1.8 | -3.75 | -8.25 |
| Weighted Avg Shares Out | 7 | 4 | 3 | 2 |
| Weighted Avg Shares Out Dil | 7 | 4 | 3 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$8 | -$8 | -$10 | -$13 |
| % Margin | -1,205.2% | -1,100.9% | -1,244.7% | -1,503.9% |